

Marta Palomo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3957297/publications.pdf>

Version: 2024-02-01

55
papers

1,245
citations

393982

19
h-index

395343

33
g-index

56
all docs

56
docs citations

56
times ranked

1604
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2022, 57, 95-105.	1.0	43
2	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
3	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. <i>Life</i> , 2022, 12, 86.	1.1	6
4	An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct. Bone Marrow Transplantation, 2022, 57, 721-728.	1.3	2
5	Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 277.e1-277.e16.	0.7	23
6	Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. <i>Frontiers in Medicine</i> , 2022, 9, 811504.	1.2	11
7	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
8	Endothelial damage and dysfunction in acute graft-versus-host disease. <i>Haematologica</i> , 2021, 106, 2147-2160.	1.7	26
9	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. <i>British Journal of Haematology</i> , 2021, 193, 181-187.	1.2	20
10	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 521-532.	1.3	15
11	Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis. <i>Platelets</i> , 2021, 32, 697-700.	1.1	1
12	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. <i>Scientific Reports</i> , 2021, 11, 3048.	1.6	25
13	Enforced sialyl-Lewis ^x (sLe ^x) display in E-selectin ligands by exofucosylation is dispensable for CD19 ^{hi} CAR ^{hi} cell activity and bone marrow homing. <i>Clinical and Translational Medicine</i> , 2021, 11, e280.	1.7	11
14	Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1948-1958.	1.9	12
15	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	1.5	6
16	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	1.3	8
17	Thrombotic microangiopathies assessment: mind the complement. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1055-1066.	1.4	14
18	P.149: Extracellular Vesicles From Patients With Diabetic Nephropathy Induce Endothelial Dysfunction Through ICAM-1 and VCAM-1 in an In Vitro Model. <i>Transplantation</i> , 2021, 105, S61-S61.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. <i>Atherosclerosis</i> , 2020, 294, 17-24.	0.4	16
20	Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1713-1723.	1.6	18
21	Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. <i>Transfusion Medicine Reviews</i> , 2020, 34, 172-177.	0.9	4
22	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?" <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3111-3113.	1.9	10
23	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. <i>Bone Marrow Transplantation</i> , 2020, 55, 2270-2278.	1.3	9
24	Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8031-8044.	1.6	23
25	Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 361.	1.5	43
26	Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 111-115.	0.6	1
27	Vascular endothelial syndromes after HCT: 2020 update. <i>Bone Marrow Transplantation</i> , 2020, 55, 1885-1887.	1.3	17
28	Circulating Biomarkers of COVID-19-Triggered Endotheliopathy: From Conjecture to Certainty. <i>Blood</i> , 2020, 136, 31-32.	0.6	4
29	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. <i>PLoS ONE</i> , 2020, 15, e0241778.	1.1	5
30	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
31	FO043ENDOTHELIAL DAMAGE IN CHRONIC KIDNEY DISEASE IS MEDIATED THROUGH HISTONE DEACETYLASE UPREGULATION AND CAN BE PREVENTED BY DEFIBROTIDE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
32	Complement Activation and Thrombotic Microangiopathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1719-1732.	2.2	57
33	Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide. <i>Frontiers in Immunology</i> , 2019, 10, 2339.	2.2	31
34	Endothelial Dysfunction in Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2019, 1, 45.	0.7	19
35	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1541-1547.	1.3	20
36	Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. <i>Clinical Endocrinology</i> , 2018, 88, 415-424.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 1287-1300.	1.1	43
38	Endothelial damage is aggravated in acute GvHD and could predict its development. <i>Bone Marrow Transplantation</i> , 2017, 52, 1317-1325.	1.3	52
39	What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. <i>Blood</i> , 2016, 127, 1719-1727.	0.6	59
40	Evidence of Defibrotide Internalization and Its Protective Effect in a Hepatic Endothelial in Vitro model. <i>Blood</i> , 2014, 124, 5960-5960.	0.6	0
41	Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus and Sirolimus on Endothelial Cells: Protective Effect of Defibrotide. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1439-1445.	2.0	73
42	NF κ B in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach. <i>PLoS ONE</i> , 2012, 7, e43374.	1.1	35
43	Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 497-506.	2.0	66
44	Endothelin-1 levels predict endothelial progenitor cell mobilization after acute myocardial infarction. <i>Microvascular Research</i> , 2011, 82, 177-181.	1.1	16
45	Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1236-1245.	1.9	40
46	Impact of Different Immunosuppressive Drugs on the Endothelium. Protective Effect of Defibrotide. <i>Blood</i> , 2011, 118, 5319-5319.	0.6	3
47	Proof of concept trial on the efficacy of sodium tungstate in human obesity. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1013-1018.	2.2	26
48	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 985-993.	2.0	109
49	The Release of Soluble Factors Contributing to Endothelial Activation and Damage after Hematopoietic Stem Cell Transplantation Is Not Limited to the Allogeneic Setting and Involves Several Pathogenic Mechanisms. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 537-546.	2.0	66
50	Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. <i>Transfusion and Apheresis Science</i> , 2008, 39, 115-121.	0.5	17
51	Inhibition of tyrosine kinase activity prevents the adhesive and cohesive properties of platelets and the expression of procoagulant activity in response to collagen. <i>Thrombosis Research</i> , 2008, 121, 873-883.	0.8	7
52	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 2970-2976.	2.4	74
53	Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation. <i>Nephron Clinical Practice</i> , 2007, 106, c1-c8.	2.3	7
54	Endothelial Dysfunction in Autologous Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4855-4855.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Alterations of ADAMTS-13 Activity as a Common Indicator of the Endothelial Dysfunction Developing in Different Thrombotic Microangiopathies.. Blood, 2006, 108, 4091-4091.	0.6	0